Clinical Trials

New Lung Associates and Tampa General Hospital have teamed up to bring you the opportunity to participate in new and exciting clinical trials. This allows our patient access to medications on the cutting-edge of technology. These studies bridge the scope of this practice from lung transplantation, cystic fibrosis, and advanced lung disease.

The studies we have which are actively enrolling patients include:  


1. A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy or as combination therapy with pirfenidone background therapy in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks.

2. Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

A Phase 1b, Multicenter, Open-label, Staggered-dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of CC-90001 for 12 Weeks in Subjects With Pulmonary Fibrosis



3. GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

This study will evaluate the effect of GS-5806 on nasal respiratory syncytial virus (RSV) viral load in RSV-positive lung transplant (LT) recipients with acute respiratory symptoms.



4. Ph 3/4 GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

The purpose of the study is two-fold: (1) to further evaluate the safety and potential immunogenicity of GLASSIA following IV administration via in-line filtration; and, (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 mg/kg Body weight (BW)/week for 25 weeks in subjects with emphysema due to congenital A1PI deficiency.


5. Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) when added to multi-drug regimen in subjects with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium Avium Complex (MAC).